Insmed Incorporated
INSMHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Insmed Incorporated (INSM) is listed under Biotechnology. The company carries a $20.39B market cap, placing it firmly in the large-cap category. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Market Cap
$20.39B
Beta
0.82
P/E (TTM)
—
P/E (Fwd)
124.21
EPS (TTM)
$-4.10
EPS (Fwd)
$0.75
ROE
-87.2%
ROA
-22.2%
Cash
$1.16B
Total Debt
$739.7M
Free CF
-$571.8M
52W Change
-43.1%
Annual Financials
Cash vs Debt
Where INSM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, INSM finished 20.46% below its 150-day moving average ($119.80) and 25.96% below its 200-day moving average ($128.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INSM overbought or oversold?
At the October 20, 2026 close, INSM's RSI(14) was 19.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.16B in cash and $739.7M in debt, INSM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$571.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -87.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $245.4M (2022) to $606.4M (2025), reflecting a 147% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Insmed Incorporated's trajectory.